← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 100%임상시험 1620상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAbbVieApproved

adalimumab (Humira, Hyrimoz, Amjevita)

Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA · TNF-α

#TNF-#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 98.85%임상시험 532상태 APPROVED
AntibodySHOTFDACuratedFDABiologicJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 97%임상시험 440상태 APPROVED
AntibodyAHOTFDACuratedFDABiologicSanofiApproved

dupilumab (Dupixent)

Atopic dermatitis, asthma, CRSwNP, EoE · IL-4Rα

#IL-4R#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 0.45%임상시험 255상태 APPROVED
AntibodySHOTFDACuratedFDABiologicNovartisApproved

secukinumab (Cosentyx)

Psoriasis, psoriatic arthritis, ankylosing spondylitis · IL-17A

#IL-17A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 78.1%임상시험 193상태 APPROVED
AntibodySHOTFDACuratedFDABiologicRegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 66.4%임상시험 163상태 APPROVED
AntibodySHOTFDACuratedFDABiologicJanssenApproved

ustekinumab (Stelara, Wezlana)

Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)

#IL-12IL-23p40#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 75%임상시험 155상태 APPROVED
AntibodySHOTFDACuratedFDABiologicRocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 68%임상시험 147상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAmgenApproved

etanercept (Enbrel, Erelzi)

RA, psoriasis, psoriatic arthritis, ankylosing spondylitis · TNF

#TNF#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 73.4%임상시험 143상태 APPROVED
AntibodySHOTFDACuratedFDABiologicNovo NordiskeffectsApproved

semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535)

Type 2 diabetes, chronic weight management, CV risk reduction (T2D) · GLP-1 receptor

#GLP-1receptor#Antibody#Approved#FDA승인#바이오모아추천+5
효능 Weight ↓14.9%임상시험 141상태 APPROVED
AntibodySHOTFDACuratedFDABiologicEli LillyApproved

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

Type 2 diabetes, chronic weight management · GLP-1 / GIP receptor

#GLP-1GIPreceptor#Antibody#Approved#FDA승인#바이오모아추천+5
효능 HbA1c ↓2.4%임상시험 117상태 APPROVED
AntibodySHOTFDACuratedFDABiologicEli LillyApproved

lebrikizumab (Ebglyss, Lilly)

Atopic dermatitis · IL-13

#IL-13#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 75%임상시험 104상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAbbVieApproved

risankizumab (Skyrizi)

Psoriasis, psoriatic arthritis, Crohn's disease · IL-23 (p19)

#IL-23p19#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 90%임상시험 91상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAmgenApproved

evolocumab (Repatha, AMG-145)

Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH · PCSK9

#PCSK9#Antibody#Approved#FDA승인#바이오모아추천+5
효능 LDL-C ↓59%임상시험 88상태 APPROVED
AntibodySHOTFDACuratedFDABiologicNovartisApproved

inclisiran (Leqvio, KJX839, ALN-PCS)

Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) · PCSK9 (siRNA)

#PCSK9siRNA#Antibody#Approved#FDA승인#바이오모아추천+5
효능 LDL-C ↓50%임상시험 52상태 APPROVED
AntibodySHOTFDACuratedFDABiologicSanofiApproved

alirocumab (Praluent, REGN727, SAR236553)

Hyperlipidemia, ASCVD, HeFH · PCSK9

#PCSK9#Antibody#Approved#FDA승인#바이오모아추천+5
효능 LDL-C ↓58%임상시험 46상태 APPROVED
AntibodyAHotstaleRocheDM1 via butelase-1 with ABD…Phase 3

trastuzumab (Herceptin)

Breast Cancer · Healthy

#Healthy#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 1044상태 ACTIVE
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 431상태 ACTIVE
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 224상태 DISCONTINUED

1 / 62 페이지

← 이전다음 →